Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q1 2026 · 10-Q
Revenue$6.56M$6.56Mno prior Q1 2025 on file Net Income-$98.54M-$98.54MN/M vs Q1 2025 EPS Diluted-$1.11-$1.11N/M vs Q1 2025 Operating Income-$108,544,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
Free Cash Flowderived-$76,137,000N/M Margins · derivedOperating margin-1654.6%
Net margin-1502.1%
ended Mar 31, 2026 · filed May 5, 2026 · 35 d after period end